Literature DB >> 20219899

Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians.

Annika Antonsson1, Adele C Green, Kylie-Ann Mallitt, Peter K O'Rourke, Michael Pawlita, Tim Waterboer, Rachel E Neale.   

Abstract

Serology has been used to indicate past infection by the human polyomaviruses BK virus (BKV) and JC virus (JCV), because the site of primary infection is not established fully. Little is known about BKV and JCV antibody stability over time. We investigated BKV and JCV seroprevalence and antibody stability over time in an Australian population-based study. Serum was collected from 458 adults participating in a longitudinal skin cancer study in Queensland in 1992, 1993 and 1996, and 117 people had a fourth sample collected in 2003. Serum samples were analysed for BKV and JCV VP1 antibodies by multiplex detection using the Luminex platform. The seroprevalence for BKV and JCV over 4.5 years was 97 and 63 %, respectively. The BKV seroprevalence was 99 % in 25-60-year-olds, and 94 % in people older than 60 years. JCV seroprevalence was around 60 % in people younger than 50 years, 68 % in people 50-70 years of age and 64 % in people older than 70 years. BKV seroprevalence was very stable over 11 years, with 96 % of people staying seropositive and 2 % remaining seronegative. JCV antibody status over time was less stable; 57 % of participants remained seropositive and 31 % seronegative. The same proportion of people (4 % each) seroconverted, seroreverted or had fluctuating JCV antibody levels. These results confirm the previously believed stability of polyomavirus antibodies, with BKV antibodies being highly stable and JCV antibodies moderately so. Thus, a single measure can be used as a reasonable indicator of long-term antibody status in epidemiological studies aiming to understand associations between polyomaviruses and disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20219899     DOI: 10.1099/vir.0.020115-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  41 in total

1.  No association between antibodies to sexually transmitted infections and colorectal hyperplastic polyps in men: Minnesota Cancer Prevention Research Unit Polyp Study.

Authors:  Andrea N Burnett-Hartman; Polly A Newcomb; Stephen M Schwartz; Roberd M Bostick; Michael Pawlita; Tim Waterboer; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

2.  Prospective Study of Human Polyomaviruses and Risk of Cutaneous Squamous Cell Carcinoma in the United States.

Authors:  Anala Gossai; Tim Waterboer; Heather H Nelson; Jennifer A Doherty; Angelika Michel; Martina Willhauck-Fleckenstein; Shohreh F Farzan; Brock C Christensen; Anne G Hoen; Ann E Perry; Michael Pawlita; Margaret R Karagas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02-11       Impact factor: 4.254

Review 3.  Strategies for delivering therapeutics across the blood-brain barrier.

Authors:  Georg C Terstappen; Axel H Meyer; Robert D Bell; Wandong Zhang
Journal:  Nat Rev Drug Discov       Date:  2021-03-01       Impact factor: 84.694

4.  Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.

Authors:  Shinji Aoyama; Masahiro Mori; Akiyuki Uzawa; Tomohiko Uchida; Hiroki Masuda; Ryohei Ohtani; Satoshi Kuwabara
Journal:  J Neurol       Date:  2018-03-12       Impact factor: 4.849

5.  JC virus infection is acquired very early in life: evidence from a longitudinal serological study.

Authors:  Francesca Elia; Sonia Villani; Federico Ambrogi; Lucia Signorini; Simone Dallari; Sandro Binda; Valeria Primache; Laura Pellegrinelli; Pasquale Ferrante; Serena Delbue
Journal:  J Neurovirol       Date:  2016-08-18       Impact factor: 2.643

6.  Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence.

Authors:  Sogol Koolaji; Narges Sistany Allahabadi; Arash Ahmadi; Sharareh Eskandarieh; Abdorreza Naser Moghadasi; Amir Reza Azimi; Mohammad Ali Sahraian
Journal:  J Neurovirol       Date:  2018-05-21       Impact factor: 2.643

7.  Anti-JC virus antibodies in rituximab-treated patients with neuromyelitis optica spectrum disorder.

Authors:  Su-Hyun Kim; Jae-Won Hyun; In Hye Jeong; AeRan Joung; Joung-Lim Yeon; Thomas Dehmel; Ortwin Adams; Bernd C Kieseier; Ho Jin Kim
Journal:  J Neurol       Date:  2015-01-06       Impact factor: 4.849

8.  Specific and quantitative detection of Human polyomaviruses BKPyV and JCPyV in the healthy Pakistani population.

Authors:  Iqra Hussain; Fareeda Tasneem; Muhammed Umer; Ayesha Pervaiz; Muslim Raza; Muhammad Imran Arshad; Naveed Shahzad
Journal:  Virol J       Date:  2017-04-24       Impact factor: 4.099

9.  Fate of the Urinary Tract Virus BK Human Polyomavirus in Source-Separated Urine.

Authors:  Heather E Goetsch; Linbo Zhao; Mariah Gnegy; Michael J Imperiale; Nancy G Love; Krista R Wigginton
Journal:  Appl Environ Microbiol       Date:  2018-03-19       Impact factor: 4.792

10.  Performance of multiplex serology in discriminating active vs past Helicobacter pylori infection in a primarily African American population in the southeastern United States.

Authors:  Julia Butt; William J Blot; Martha J Shrubsole; Matthew G Varga; Laura H Hendrix; Sydnee Crankshaw; Tim Waterboer; Michael Pawlita; Meira Epplein
Journal:  Helicobacter       Date:  2019-11-20       Impact factor: 5.753

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.